Victory Capital Management
RYTM icon

Victory Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Victory Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$853K Sell
7,679
-12,825
-63% -$1.16M ﹤0.01% 1950
2026
Q1 		$1.78M Sell
20,504
-24,877
-55% -$2.42M ﹤0.01% 1640
2025
Q4 		$4.86M Buy
45,381
+2,498
+6% +$265K ﹤0.01% 1325
2025
Q3 		$4.33M Buy
42,883
+26,642
+164% +$2.47M ﹤0.01% 1383
2025
Q2 		$1.03M Sell
16,241
-1,085
-6% -$66.4K ﹤0.01% 1841
2025
Q1 		$918K Buy
17,326
+174
+1% +$9.65K ﹤0.01% 1840
2024
Q4 		$960K Sell
17,152
-1,034
-6% -$57.1K ﹤0.01% 1829
2024
Q3 		$953K Buy
18,186
+11,137
+158% +$534K ﹤0.01% 1795
2024
Q2 		$289K Sell
7,049
-8,036
-53% -$321K ﹤0.01% 2109
2024
Q1 		$654K Sell
15,085
-167,212
-92% -$7.32M ﹤0.01% 1903
2023
Q4 		$8.38M Buy
182,297
+162,247
+809% +$5.12M 0.01% 1118
2023
Q3 		$460K Buy
+20,050
New +$449K ﹤0.01% 2012
2020
Q2 		– Sell
-4,274
Closed -$65K – 3142
2020
Q1 		$65K Sell
4,274
-1,793
-30% -$32.1K ﹤0.01% 2446
2019
Q4 		$139K Buy
6,067
+3,277
+117% +$72.8K ﹤0.01% 2422
2019
Q3 		$60K Buy
+2,790
New +$59.9K ﹤0.01% 2606

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Victory Capital Management's RYTM Position: Q2 2026 in Review

Victory Capital Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 63% in Q2 2026, selling an estimated $1.16M and leaving 7,679 shares worth $853K. The position accounts for ﹤0.01% of the portfolio, ranked #1950.

Victory Capital Management first reported a position in RYTM in Q3 2019 and has held it in 15 quarters since. The position peaked at $8.38M in Q4 2023. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Victory Capital Management held 7,679 shares of Rhythm Pharmaceuticals worth $853K as of Q2 2026.
  • Victory Capital Management sold 12,825 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $1.16M.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1950 holding.
  • Victory Capital Management first reported a position in Rhythm Pharmaceuticals in Q3 2019 and has held it in 15 quarters since.
  • Victory Capital Management's Rhythm Pharmaceuticals position peaked at $8.38M in Q4 2023.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.